|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patard JJ, Leray E, Rioux-Leclercq N,
Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani
W, Abbou CC, et al: Prognostic value of histologic subtypes in
renal cell carcinoma: A multicenter experience. J Clin Oncol.
23:2763–2771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lardas M, Stewart F, Scrimgeour D, Hofmann
F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M,
et al: Systematic review of surgical management of nonmetastatic
renal cell carcinoma with vena caval thrombus. Eur Urol.
70:265–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part a: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davis ID, Xie W, Pezaro C, Donskov F,
Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, et
al: Efficacy of second-line targeted therapy for renal cell
carcinoma according to change from baseline in international
metastatic renal cell carcinoma database consortium prognostic
category. Eur Urol. 71:970–978. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cloney R: Non-coding RNA: Deciphering the
rules of microRNA targeting. Nat Rev Genet. 17:7182016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsui M and Corey DR: Non-coding RNAs as
drug targets. Nat Rev Drug Discov. 16:167–179. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lumayag S, Haldin CE, Corbett NJ, Wahlin
KJ, Cowan C, Turturro S, Larsen PE, Kovacs B, Witmer PD, Valle D,
et al: Inactivation of the microRNA-183/96/182 cluster results in
syndromic retinal degeneration. Proc Natl Acad Sci USA. 110:pp.
E507–E516. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huangfu L, Liang H, Wang G, Su X, Li L, Du
Z, Hu M, Dong Y, Bai X, Liu T, et al: miR-183 regulates autophagy
and apoptosis in colorectal cancer through targeting of UVRAG.
Oncotarget. 7:4735–4745. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miao F, Zhu J, Chen Y, Tang N, Wang X and
Li X: MicroRNA-183-5p promotes the proliferation, invasion and
metastasis of human pancreatic adenocarcinoma cells. Oncol Lett.
11:134–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu C, Deng X, Wu J, Zhang J, Yang H, Fu
S, Zhang Y, Han Y, Zou Y, Chen Z and Lin S: MicroRNA-183 promotes
migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma
initiating cells via PTPN4 inhibition. Tumour Biol. 37:11289–11297.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C, Deng L, Zhi Q, Meng Q, Qian A, Sang
H, Li X and Xia J: MicroRNA-183 functions as an oncogene by
regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem.
16:447–455. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng Y, Xiang G, Meng Y and Dong R:
MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in
human breast cancer by targeting the PDCD4. Reprod Biol.
16:225–233. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X,
Jin X and Tian X: MicroRNA-183 functions as the tumor suppressor
via inhibiting cellular invasion and metastasis by targeting MMP-9
in cervical cancer. Gynecol Oncol. 141:166–174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Q, Di W, Dong Y, Lu G, Yu J, Li J
and Li P: High serum miR-183 level is associated with poor
responsiveness of renal cancer to natural killer cells. Tumour
Biol. 36:9245–9249. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ueno K, Hirata H, Shahryari V, Deng G,
Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: microRNA-183 is an
oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer.
108:1659–1667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bi DP, Yin CH, Zhang XY, Yang NN and Xu
JY: MiR-183 functions as an oncogene by targeting ABCA1 in colon
cancer. Oncol Rep. 35:2873–2879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klaus A and Birchmeier W: Wnt signalling
and its impact on development and cancer. Nat Rev Cancer.
8:387–398. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Veeck J and Dahl E: Targeting the Wnt
pathway in cancer: The emerging role of Dickkopf-3. Biochim Biophys
Acta. 1825:18–28. 2012.PubMed/NCBI
|
|
25
|
Ueno K, Hirata H, Majid S, Chen Y, Zaman
MS, Tabatabai ZL, Hinoda Y and Dahiya R: Wnt antagonist DICKKOPF-3
(Dkk-3) induces apoptosis in human renal cell carcinoma. Mol
Carcinog. 50:449–457. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo CC, Zhang XL, Yang B, Geng J, Peng B
and Zheng JH: Decreased expression of Dkk1 and Dkk3 in human clear
cell renal cell carcinoma. Mol Med Rep. 9:2367–2373. 2014.
View Article : Google Scholar : PubMed/NCBI
|
